Perrigo Co. (PRGO) Rating Lowered to Sell at Zacks Investment Research


According to Zacks, "Perrigo has a presence in the OTC market and sells generic and specialty pharma drugs as well. The company had provided a dull outlook for both 2016 earnings and revenues, which is concerning.



from Biotech News